(v3.1.0.9011) Use top_n_microorganisms() in the WISCA examples of the index, manual and vignette, and reword the WISCA prior weight warning to also cover small groups (#337)

This commit is contained in:
dr. M.S. (Matthijs) Berends committed 2026-10-30 12:45:56 +01:00
1 parent fdfdadae14
commit 944078c4bc
7 files changed
+33 -30

No files matched your search

+12 -12
View File
@@ -217,36 +217,36 @@ credible intervals via Bayesian simulation. See `vignette("WISCA")` for
the full explanation.
``` r
wisca(example_isolates,
wisca(top_n_microorganisms(example_isolates, n = 10), # 10 most common species
antimicrobials = c("TZP", "TZP+TOB", "TZP+GEN"),
minimum = 10) # Recommended threshold: >=30
```
| Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:------------------------|:-------------------------------------|:-------------------------------------|
| 72.5% (67.7-77.1%) | 96% (95.1-96.9%) | 92.1% (89.3-94.4%) |
| 73% (67.7-79%) | 98.7% (98-99.2%) | 93.8% (90.5-96.6%) |
WISCA supports stratification by any clinical variable, so you can
generate syndrome-specific or ward-specific coverage estimates:
``` r
wisca(example_isolates,
wisca(top_n_microorganisms(example_isolates, n = 10),
antimicrobials = c("TZP", "TZP+TOB", "TZP+GEN"),
syndromic_group = "ward",
minimum = 10) # Recommended threshold: >=30
#> Warning: In 6 of 9 WISCA regimen(s) or group(s), the prior weight of 1 per pathogen accounts for more than
#> 5% of the pathogen incidence (up to 13.3%), since many pathogens occur only rarely. Because WISCA
#> gives every pathogen a prior weight of 1 (Bielicki et al., 2016), such rare pathogens can strongly
#> lower the estimated coverage without reflecting the clinical expectation. Consider limiting the
#> analysis to the most common pathogens with `top_n_microorganisms()`, or grouping rare pathogens
#> before running WISCA.
#> Warning: In 3 of 9 WISCA regimen(s) or group(s), the prior weight of 1 per pathogen accounts for more than
#> 5% of the pathogen incidence (up to 6.4%), since there are few isolates relative to the number of
#> pathogens, i.e., rare pathogens or a small group. Because WISCA gives every pathogen a prior weight
#> of 1 (Bielicki et al., 2016), this can strongly lower the estimated coverage without reflecting the
#> clinical expectation. Consider limiting the analysis to the most common pathogens with
#> `top_n_microorganisms()`, or using fewer and larger groups.
```
| Syndromic Group | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|:----------------|:------------------------|:-------------------------------------|:-------------------------------------|
| Clinical | 78% (72.7-83.4%) | 96.3% (95.1-97.3%) | 93% (89.4-95.7%) |
| ICU | 59.7% (53.5-67.9%) | 92.2% (90-94.3%) | 88.2% (83.4-92.2%) |
| Outpatient | 67.9% (51.9-84.7%) | 92.8% (88.2-96.6%) | 79.8% (64.9-92.9%) |
| Clinical | 78.9% (72.8-85.6%) | 98.7% (97.8-99.3%) | 94.5% (90.3-97.6%) |
| ICU | 57.3% (48.9-69.5%) | 97.5% (95.7-98.8%) | 91.7% (85.8-96.3%) |
| Outpatient | 68% (49.4-88.5%) | 95.7% (90.7-98.7%) | 79.3% (62.7-93.8%) |
**For AMR surveillance**, traditional antibiograms remain the right tool
for tracking resistance per species over time: